On April 2, 2024 KiraGen Bio, a pioneering biotech company in the field of innovative cellular therapies for solid tumors, is pleased to announce today a strategic partnership with Flash BioSolutions, a leading CDMO providing state-of-the-art lentiviral particles (Press release, KiraGen Bio, APR 2, 2024, View Source [SID1234644884]). This collaboration aims to fully harness the potential of CAR-T (Chimeric Antigen Receptor T-cell) therapies in cancer treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through this alliance, KiraGen Bio will leverage the advanced expertise of Flash BioSolutions and its flagship technology, LentiCare. This cutting-edge lentiviral platform will be seamlessly integrated into the development of KiraGen Bio’s groundbreaking CAR-T therapies, playing a crucial role in the Proof of Concept stage and beyond.

The revolutionary aspect of this partnership lies in the synergistic combination of KiraGen Bio’s proprietary AI-driven platform, KiraLOGIC, and Flash BioSolutions’ state-of-the-art LentiCare technology. KiraLOGIC employs advanced machine learning algorithms to rationally design CAR-T cells equipped with a combination of highly multiplexed gene edits, rendering them resistant to the immunosuppressive tumor microenvironment. By integrating these AI-powered gene editing capabilities with the high-quality lentiviral vectors provided by Flash BioSolutions, KiraGen Bio is poised to unlock the full potential of CAR-T therapies for solid tumors, addressing a critical unmet need in cancer treatment.

"Our KiraLOGIC platform leverages AI to rationally design CAR-T cells resistant to immunosuppression, unlocking the potential of cell therapies for solid tumors. Partnering with Flash BioSolutions, a leader in lentiviral vector manufacturing, is pivotal in advancing our multiplex gene-edited CAR-T therapies. Their LentiCare technology ensures high-quality lentiviral vectors, essential for generating robust preclinical data and propelling our therapies towards clinical development. Together, we are poised to accelerate scientific progress and deliver transformative treatments to patients in need," stated Ryan Murray, PhD, CSO & Co-Founder of KiraGen Bio.

"At KiraGen, our unwavering commitment is to bring our revolutionary TME-Guard technology to patients as quickly and broadly as possible. Collaborating with Flash BioSolutions is a significant milestone in realizing this vision. Their deep expertise in lentiviral manufacturing will be instrumental as we rapidly advance our innovative cell therapies through preclinical development and into the clinic. This strategic partnership is key to accelerating our lead programs, forging powerful industry and academic alliances, and building a robust and sustainable pipeline. By joining forces with Flash BioSolutions, we are creating a powerful model that can drive transformative impact for patients while generating value for our investors, as we work to establish KiraGen as a pioneer in solid tumor cell therapy," added Aaron Edwards, CEO & Co-Founder of KiraGen Bio.

"Flash BioSolutions is thrilled to collaborate with KiraGen Bio in reshaping the paradigm of CAR-T therapies for solid tumors," stated Jérôme Bédier, CEO of Flash BioSolutions. "Through the potent fusion of our expertise and state-of-the-art technologies, we are steadfast in our commitment to propelling scientific innovation and introducing revolutionary treatment options for patients confronting this formidable disease."

This partnership between Flash BioSolutions and KiraGen Bio embodies the commitment of both companies to push the boundaries of research to improve the lives of cancer patients. Together, they aspire to open new perspectives in the treatment of solid tumors and bring renewed hope to those battling this disease.